(Q37860735)

24 August 2017

1 reference

title

Advances in early diagnosis and therapy of pancreatic cancer (English)

1 reference

24 August 2017

0 references

1 reference

Qiang Xu

1

1 reference

24 August 2017

Tai-Ping Zhang

series ordinal

2

1 reference

24 August 2017

Yu-Pei Zhao

series ordinal

3

1 reference

24 August 2017

1 April 2011

1 reference

Hepatobiliary & Pancreatic Diseases International

24 August 2017

1 reference

24 August 2017

10

1 reference

24 August 2017

2

1 reference

24 August 2017

128-135

1 reference

24 August 2017

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Cancer incidence trends in urban shanghai, 1972-1994: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Advances in counselling and surveillance of patients at risk for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Early detection of pancreatic cancer: why, who, and how to screen

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Pancreatic cancer--EUS and early diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Identifying molecular markers for the early detection of pancreatic neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic Adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

CEACAM1, a novel serum biomarker for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Second-look operation for unresectable pancreatic ductal adenocarcinoma at a high-volume center

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

The role of extended lymphadenectomy for adenocarcinoma of the head of the pancreas: strength of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Resectable adenocarcinomas in the pancreatic head: the retroperitoneal resection margin is an independent prognostic factor

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Redefining the R1 resection in pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Pancreatic cancer--is the wall crumbling?

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Novel advances in pancreatic cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Adjuvant radiotherapy for resected pancreatic cancer: a lack of benefit or a lack of adequate trials?

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

The case for adjuvant chemoradiation for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Role of adjuvant therapy in the management of pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Intraoperative radiotherapy in pancreatic cancer: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Borderline resectable pancreatic cancer: a new classification for an old challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Borderline resectable pancreatic cancer: the importance of this emerging stage of disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Pancreatic Resections after Chemoradiotherapy for Locally Advanced Ductal Adenocarcinoma: Analysis of Perioperative Outcome and Survival

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

Neoadjuvant therapy for pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1499-3872%2811%2960021-0

7 January 2021

10.1016/S1499-3872(11)60021-0

Identifiers

DOI

0 references

1 reference